Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRS Aclaris Therapeutics	$1.27 +0.8%	$1.32	$0.95 ▼ $5.17	$136.43M	0.42	1.18 million shs	623,976 shs
ATHE Alterity Therapeutics	$4.28 +0.7%	$3.58	$1.00 ▼ $5.87	$37.95M	0.65	143,295 shs	28,836 shs
EPRX Eupraxia Pharmaceuticals	$3.86 -0.3%	$3.58	$2.20 ▼ $4.48	$138.38M	N/A	12,893 shs	34,225 shs
FATE Fate Therapeutics	$1.22 +5.2%	$1.05	$0.66 ▼ $5.92	$139.82M	2.32	2.23 million shs	1.40 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRS Aclaris Therapeutics	+0.79%	-5.93%	-5.22%	-39.67%	+14.41%
ATHE Alterity Therapeutics	+0.71%	+1.90%	+22.99%	+3.38%	+114.00%
EPRX Eupraxia Pharmaceuticals	-0.26%	-1.03%	+1.31%	-10.02%	+35.44%
FATE Fate Therapeutics	+5.17%	-2.40%	-4.69%	+5.17%	-65.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRS Aclaris Therapeutics	2.7054 of 5 stars	3.6	2.0	0.0	3.0	1.7	1.3
ATHE Alterity Therapeutics	2.5237 of 5 stars	3.3	5.0	0.0	2.7	1.7	0.0
EPRX Eupraxia Pharmaceuticals	2.9317 of 5 stars	3.7	3.0	0.0	3.3	0.0	0.6
FATE Fate Therapeutics	4.4873 of 5 stars	4.1	3.0	4.7	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRS Aclaris Therapeutics	3.13	Buy	$10.00	687.40% Upside
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	180.37% Upside
EPRX Eupraxia Pharmaceuticals	3.33	Buy	$10.50	172.02% Upside
FATE Fate Therapeutics	2.22	Hold	$4.14	239.58% Upside

Current Analyst Ratings Breakdown

Latest ATHE, ACRS, FATE, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ACRS Aclaris Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $16.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/9/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$15.00 ➝ $9.00
3/18/2025	ACRS Aclaris Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight
3/7/2025	ACRS Aclaris Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$15.00
3/6/2025	FATE Fate Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$5.00 ➝ $3.00
3/6/2025	FATE Fate Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$5.00 ➝ $4.00
3/6/2025	FATE Fate Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$5.00 ➝ $5.00
3/6/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRS Aclaris Therapeutics	$17.78M	7.74	N/A	N/A	$2.22 per share	0.57
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
FATE Fate Therapeutics	$13.34M	10.48	N/A	N/A	$3.74 per share	0.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRS Aclaris Therapeutics	-$88.48M	-$1.39	N/A	N/A	N/A	-136.65%	-40.26%	-31.71%	8/6/2025 (Estimated)
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$28.22M	-$0.76	N/A	N/A	N/A	N/A	-219.64%	-96.00%	8/6/2025 (Estimated)
FATE Fate Therapeutics	-$160.93M	-$1.49	N/A	N/A	N/A	-1,325.43%	-45.88%	-33.95%	8/12/2025 (Estimated)

Latest ATHE, ACRS, FATE, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/6/2025	Q1 2025	ACRS Aclaris Therapeutics	-$0.19	-$0.12	+$0.07	-$0.12	$3.55 million	N/A
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A
3/20/2025	Q4 2024	EPRX Eupraxia Pharmaceuticals	-$0.20	-$0.21	-$0.01	-$0.21	N/A	N/A
3/5/2025	Q4 2024	FATE Fate Therapeutics	-$0.44	-$0.31	+$0.13	-$0.44	$1.57 million	$1.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRS Aclaris Therapeutics	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRS Aclaris Therapeutics	N/A	7.03	7.03
ATHE Alterity Therapeutics	N/A	3.54	3.54
EPRX Eupraxia Pharmaceuticals	N/A	4.17	4.17
FATE Fate Therapeutics	N/A	8.29	8.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRS Aclaris Therapeutics	98.34%
ATHE Alterity Therapeutics	2.14%
EPRX Eupraxia Pharmaceuticals	N/A
FATE Fate Therapeutics	97.54%

Insider Ownership

Company	Insider Ownership
ACRS Aclaris Therapeutics	6.40%
ATHE Alterity Therapeutics	38.80%
EPRX Eupraxia Pharmaceuticals	N/A
FATE Fate Therapeutics	5.51%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRS Aclaris Therapeutics	100	108.28 million	66.86 million	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.35 million	Not Optionable
EPRX Eupraxia Pharmaceuticals	29	35.85 million	N/A	N/A
FATE Fate Therapeutics	550	114.60 million	108.20 million	Optionable

ATHE, ACRS, FATE, and EPRX Headlines

Recent News About These Companies

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts

May 28 at 2:05 AM | marketbeat.com

Fate Therapeutics, Inc. (NASDAQ:FATE) Stock Holdings Trimmed by Woodline Partners LP

May 27 at 4:32 AM | marketbeat.com

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Analysts

May 27 at 2:06 AM | americanbankingnews.com

D. E. Shaw & Co. Inc. Decreases Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

May 22, 2025 | marketbeat.com

Vestal Point Capital LP Increases Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

May 21, 2025 | marketbeat.com

Fate Therapeutics, Inc. (NASDAQ:FATE) Holdings Raised by Tang Capital Management LLC

May 20, 2025 | marketbeat.com

Sphera Funds Management LTD. Purchases Shares of 397,177 Fate Therapeutics, Inc. (NASDAQ:FATE)

May 18, 2025 | marketbeat.com

Fate Therapeutics (NASDAQ:FATE) Upgraded at StockNews.com

May 18, 2025 | americanbankingnews.com

Q2 Earnings Estimate for Fate Therapeutics Issued By Wedbush

May 18, 2025 | americanbankingnews.com

Needham Remains a Hold on Fate Therapeutics (FATE)

May 16, 2025 | theglobeandmail.com

Barclays Reaffirms Their Buy Rating on Fate Therapeutics (FATE)

May 16, 2025 | theglobeandmail.com

Fate Therapeutics (FATE) Receives a Hold from Wedbush

May 16, 2025 | theglobeandmail.com

Fate Therapeutics (NASDAQ:FATE) Receives Hold Rating from Needham & Company LLC

May 16, 2025 | marketbeat.com

Fate Therapeutics First Quarter 2025 Earnings: Beats Expectations

May 15, 2025 | finance.yahoo.com

Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Purchased by Dimensional Fund Advisors LP

May 15, 2025 | marketbeat.com

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

May 14, 2025 | zacks.com

Integral Health Asset Management LLC Lowers Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

May 14, 2025 | marketbeat.com

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 13, 2025 | globenewswire.com

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

May 9, 2025 | seekingalpha.com

Baker BROS. Advisors LP Grows Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

May 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE, ACRS, FATE, and EPRX Company Descriptions

Aclaris Therapeutics NASDAQ:ACRS

$1.27 +0.01 (+0.79%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.26 -0.01 (-0.71%)

As of 05/27/2025 07:38 PM Eastern

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Alterity Therapeutics NASDAQ:ATHE

$4.28 +0.03 (+0.71%)

Closing price 05/27/2025 03:57 PM Eastern

Extended Trading

$4.28 0.00 (0.00%)

As of 05/27/2025 04:04 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$3.86 -0.01 (-0.26%)

Closing price 05/27/2025 03:59 PM Eastern

Extended Trading

$3.84 -0.02 (-0.52%)

As of 05/27/2025 05:59 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Fate Therapeutics NASDAQ:FATE

$1.22 +0.06 (+5.17%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.24 +0.02 (+1.23%)

As of 05/27/2025 05:47 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time